The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy
A Multicenter, Randomized, Open-Label, Active-Controlled, Trial to Evaluate the Safety and Efficacy of Rifaximin 550 mg With and Without Lactulose in Subjects With a History of Recurrent Overt Hepatic Encephalopathy
Sponsor: Bausch Health Americas, Inc.
Listed as NCT01842581, this PHASE4 trial focuses on Cirrhosis and Hepatic Encephalopathy and remains completed. Sponsored by Bausch Health Americas, Inc., it has been updated 11 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE4
▶ Show 6 earlier versions
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE4
-
Jun 2019 — Oct 2019 [monthly]
Completed PHASE4
-
Jun 2018 — Jun 2019 [monthly]
Completed PHASE4
-
May 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Feb 2017 — May 2017 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Jan 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bausch Health Americas, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .